Back to Search
Start Over
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
- Source :
- Business Wire. May 1, 2019
- Publication Year :
- 2019
-
Abstract
- - COSMIC-313 is the third phase 3 pivotal trial to investigate cabozantinib in combination with immune checkpoint inhibitors - ALAMEDA, Calif. -- Exelixis, Inc. (NASDAQ: EXEL) today announced that it [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Business Wire
- Publication Type :
- News
- Accession number :
- edsgcl.584132491